ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer

Lung Cancer

Volumn 80, Issue 3, 2013, Pages 278-283

  Preusser, Matthias ^a,f   Berghoff, Anna S ^b,f   Ilhan Mutlu, Ayseguel ^a,f   Magerle, Manuel ^a,f   Dinhof, Carina ^a,f   Widhalm, Georg ^a,f   Dieckmann, Karin ^a,f   Marosi, Christine ^a,f   Wöhrer, Adelheid ^b,f   Hackl, Monika ^c   Zöchbauer Müller, Sabine ^a   von Deimling, Andreas ^d   Schoppmann, Sebastian F ^a   Zielinski, Christoph C ^a,f   Streubel, Berthold ^e   Birner, Peter ^a,d,f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Austrian National Cancer Registry   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^f Central Nervous System Tumours Unit (CCC CNS)   (Austria)

Author keywords

ALK; Brain metastases; Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MICROTUBULE ASSOCIATED PROTEIN LIKE 4; PROTEIN; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CHROMOSOME INVERSION; CHROMOSOME REARRANGEMENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CHROMOSOME INVERSION; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; SERINE ENDOPEPTIDASES; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC;

EID: 84877136472     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.01.019     Document Type: Article

References (44)

1. Goldstraw P., Ball D., Jett J.R., Le Chevalier T., Lim E., Nicholson A.G., et al. Non-small-cell lung cancer. Lancet 2011, 378:1727-1740.
2. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
3. Scagliotti G., Stahel R.A., Rosell R., Thatcher N., Soria J.C. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer 2012, 48:961-973.
4. Gandhi L., Janne P.A. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012, 18:3737-3742.
5. Okamoto I., Nakagawa K. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects. Cancer Sci 2012, 103:1391-1396.
6. Heuckmann J.M., Balke-Want H., Malchers F., Peifer M., Sos M.L., Koker M., et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012, 18:4682-4690.
7. Preusser M., Capper D., Ilhan-Mutlu A., Berghoff A.S., Birner P., Bartsch R., et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012, 123:205-222.
8. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
9. Rochet N.M., Kottschade L.A., Markovic S.N. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011, 365:2439-2441.
10. Chiu C.H., Tsai C.M., Chen Y.M., Chiang S.C., Liou J.L., Perng R.P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005, 47:129-138.
11. Kim J.E., Lee D.H., Choi Y., Yoon D.H., Kim S.W., Suh C., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009, 65:351-354.
12. Porta R., Sanchez-Torres J.M., Paz-Ares L., Massuti B., Reguart N., Mayo C., et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011, 37:624-631.
13. Pestalozzi B.C., Zahrieh D., Price K.N., Holmberg S.B., Lindtner J., Collins J., et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17:935-944.
14. Nguyen D.X., Chiang A.C., Zhang X.H., Kim J.Y., Kris M.G., Ladanyi M., et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009, 138:51-62.
15. Yang P., Kulig K., Boland J.M., Erickson-Johnson M.R., Oliveira A.M., Wampfler J., et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012, 7:90-97.
16. Doebele R.C., Lu X., Sumey C., Maxson D.A., Weickhardt A.J., Oton A.B., et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012, 118:4502-4511.
17. Wohrer A., Waldhor T., Heinzl H., Hackl M., Feichtinger J., Gruber-Mosenbacher U., et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 2009, 95:401-411.
18. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
19. Birner P., Beer A., Vinatzer U., Stary S., Hoftberger R., Nirtl N., et al. MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clin Cancer Res 2012, 18:1879-1887.
20. Mino-Kenudson M., Chirieac L.R., Law K., Hornick J.L., Lindeman N., Mark E.J., et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010, 16:1561-1571.
21. Salido M., Pijuan L., Galvan A.B., Gimeno J., Canadas I., Rodriguez-Rivera M., et al. ALK status in a primary lung tumour and metachronous metastases. Histopathology 2012, 60:843-845.
22. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 29:e443-e445.
23. Ahn H.K., Han B., Lee S.J., Lim T., Sun J.M., Ahn J.S., et al. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. Lung Cancer 2012, 76:253-254.
24. Falk A.T., Poudenx M., Otto J., Ghalloussi H., Barriere J. Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report. Lung Cancer 2012, 78:282-284.
25. Chi A.S., Batchelor T.T., Kwak E.L., Clark J.W., Wang D.L., Wilner K.D., et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012, 30:e30-e33.
26. Cabezon-Gutierrez L., Khosravi-Shahi P., Diaz-Munoz-de-la-Espada V.M., Carrion-Galindo J.R., Erana-Tomas I., Castro-Otero M. ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment. Lung 2012, 190:381-388.
27. Ardini E., Menichincheri M., De Ponti C. Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Therapeutics 2009, 8:243. abstr.
28. Clayton A.J., Danson S., Jolly S., Ryder W.D., Burt P.A., Stewart A.L., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91:639-643.
29. Chun S.G., Choe K.S., Iyengar P., Yordy J.S., Timmerman R.D. Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?. Cancer Biol Ther 2012, 13.
30. Just P.A., Cazes A., Audebourg A., Cessot A., Pallier K., Danel C., et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Lung Cancer 2012, 76:309-315.
31. Popat S., Gonzalez D., Min T., Swansbury J., Dainton M., Croud J.G., et al. ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung Cancer 2012, 75:300-305.
32. Park H.S., Lee J.K., Kim D.W., Kulig K., Kim T.M., Lee S.H., et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012, 77:288-292.
33. Thunnissen E., Bubendorf L., Dietel M., Elmberger G., Kerr K., Lopez-Rios F., et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012, 461:245-257.
34. Paik J.H., Choi C.M., Kim H., Jang S.J., Choe G., Kim D.K., et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012, 76:403-409.
35. Kim H., Yoo S.B., Choe J.Y., Paik J.H., Xu X., Nitta H., et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011, 6:1359-1366.
36. Yi E.S., Boland J.M., Maleszewski J.J., Roden A.C., Oliveira A.M., Aubry M.C., et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011, 6:459-465.
37. McLeer-Florin A., Moro-Sibilot D., Melis A., Salameire D., Lefebvre C., Ceccaldi F., Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study, et al. J Thorac Oncol 2012, 7:348-354.
38. Hofman P., Ilie M., Hofman V., Roux S., Valent A., Bernheim A., et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012, 23:1738-1743.
39. Conklin C.M., Craddock K.J., Have C., Laskin J., Couture C., Ionescu D.N. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2012, 8:45-51.
40. Wallander M.L., Geiersbach K.B., Tripp S.R., Layfield L.J. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 2012, 136:796-803.
41. Salido M., Pijuan L., Martinez-Aviles L., Galvan A.B., Canadas I., Rovira A., et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011, 6:21-27.
42. Pelosi G., Gasparini P., Cavazza A., Rossi G., Graziano P., Barbareschi M., et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer 2012, 77:507-514.
43. Schoppmann SF, Streubel B, Birner P. Amplification but not translocation of ALK is a frequent event in esophageal cancer. Eur J Cancer., (in press).
44. Tuma R.S. ALK gene amplified in most inflammatory breast cancers. J Natl Cancer Inst 2012, 104:87-88.